Sign inJoin waitlistJoin the waitlist

Eugene Schiff

Director, Schiff Center for Liver Diseases · Jackson Memorial Hospital

Credentials: · ·

History

Schiff Center for Liver Diseases · Jackson Memorial Hospital
Present
University of Miami/Jackson Health System
Present
Schiff Center for Liver Diseases · University of Miami/Jackson Health System
Present

Gastroenterology
University of Texas Southwestern Medical Center
1966–1969
Transplant Hepatology
University of Miami/Jackson Health System
1965–1966
Cincinnati General Hospital in Cincinnati
1962–1965
Columbia Univ Coll of Phys & Surgeons
1958–1962
University
1954–1958

Research

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
New England Journal of Medicine · 1998 · 2,880 citations
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
The American Journal of Gastroenterology · 2002 · Last of 9 authors · 1,679 citations
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
New England Journal of Medicine · 1989 · 1,618 citations

LJ
Lennox Jeffers
106 papers
KR
Kuchikula Reddy
98 papers
AT
Andreas Tzakis
44 papers
AR
Arie Regev
26 papers
JD
Jules Dienstag
21 papers
RP
Robert Perrillo
21 papers
Stuart Gordon
21 papers · 7 as a fellow
JN
Jose Nery
20 papers
Mitchell Shiffman
19 papers
Christopher O’Brien
17 papers · 2 as a fellow
JM
John McHutchison
17 papers
EM
Enrique Molina
16 papers

Clinical trials

Rapid Diagnostics for HIV and Hepatitis
Principal investigator · Withdrawn
MedMira Laboratories Inc.
2014–2015
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
Site PI · Recruiting · Phase 3
Takeda
2024–2028
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Site PI · Recruiting · Phase 3
Takeda
2023–2031